US company to cover cost of manufacturing centre but questions remain about British government investment
The UK government has refused to reveal how much it has spent on a 10-year deal with the US pharmaceutical company Moderna—despite growing public interest in the UK’s vaccine manufacturing capability.
Agreed in December, the £1 billion deal includes plans for a vaccine research and manufacturing facility with the capacity to produce up to 250 million vaccines a year, with the first due to be made in 2025. The company has also committed to funding PhD places and university research programmes.